Sangamo Therapeutics Files 8-K for 'Other Event' on Feb 5

TL;DR

**SGMO filed an 8-K for an 'Other Event' on Feb 5, but the filing lacks specific details.**

AI Summary

Sangamo Therapeutics, Inc. (SGMO) filed an 8-K on February 6, 2024, reporting an 'Other Event' that occurred on February 5, 2024. This filing indicates a routine disclosure of an event that the company deems important enough to report to the SEC, but the specific details of the event are not provided within this particular filing. For investors, this means that while Sangamo is fulfilling its regulatory obligations, the actual impact or nature of the event remains unclear without further information, which could introduce uncertainty regarding the company's operational or financial outlook.

Why It Matters

This filing signals that an event occurred at Sangamo Therapeutics that the company considers material, but without details, investors are left in the dark about its potential impact on the stock price or future operations.

Risk Assessment

Risk Level: medium — The lack of specific details about the 'Other Event' creates uncertainty, which is a moderate risk for investors as the nature of the event could be positive or negative.

Analyst Insight

A smart investor would monitor Sangamo Therapeutics (SGMO) for follow-up announcements or filings that provide specific details about the 'Other Event' reported on February 5, 2024, before making any investment decisions.

Key Players & Entities

• SANGAMO THERAPEUTICS, INC. (company) — the registrant filing the 8-K
• February 5, 2024 (date) — date of the earliest event reported
• February 6, 2024 (date) — date the 8-K was filed
• 000-30171 (other) — Commission File Number for Sangamo Therapeutics
• SGMO (other) — Trading Symbol for Sangamo Therapeutics
• Nasdaq Global Select Market (other) — exchange where Sangamo's Common Stock is registered

Forward-Looking Statements

• Sangamo Therapeutics will release more details about the 'Other Event' in a subsequent filing or press release. (SANGAMO THERAPEUTICS, INC.) — medium confidence, target: 2024-02-12

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value per share SGMO Nasdaq Global

Filing Documents

• sgmo-20240205.htm (8-K) — 68KB
• sgmo-20240205_g1.jpg (GRAPHIC) — 462KB
• sgmo-20240205_g10.jpg (GRAPHIC) — 55KB
• sgmo-20240205_g11.jpg (GRAPHIC) — 54KB
• sgmo-20240205_g12.jpg (GRAPHIC) — 50KB
• sgmo-20240205_g13.jpg (GRAPHIC) — 72KB
• sgmo-20240205_g14.jpg (GRAPHIC) — 351KB
• sgmo-20240205_g15.jpg (GRAPHIC) — 370KB
• sgmo-20240205_g2.jpg (GRAPHIC) — 378KB
• sgmo-20240205_g3.jpg (GRAPHIC) — 300KB
• sgmo-20240205_g4.jpg (GRAPHIC) — 35KB
• sgmo-20240205_g5.jpg (GRAPHIC) — 44KB
• sgmo-20240205_g6.jpg (GRAPHIC) — 40KB
• sgmo-20240205_g7.jpg (GRAPHIC) — 46KB
• sgmo-20240205_g8.jpg (GRAPHIC) — 38KB
• sgmo-20240205_g9.jpg (GRAPHIC) — 52KB
• 0001628280-24-003506.txt ( ) — 5357KB
• sgmo-20240205.xsd (EX-101.SCH) — 2KB
• sgmo-20240205_def.xml (EX-101.DEF) — 14KB
• sgmo-20240205_lab.xml (EX-101.LAB) — 28KB
• sgmo-20240205_pre.xml (EX-101.PRE) — 15KB
• sgmo-20240205_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On February 5, 2024, Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") announced updated preliminary clinical data from its Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease, in advance of a presentation at the 20 th Annual WORLD Symposium on February 7, 2024. A summary of the data is below. This announcement included data on the 24 patients treated with isaralgagene civaparvovec as of the data cutoff date of September 19, 2023. Since the data cutoff date, an additional four patients have been dosed in the Phase 1/2 STAAR study, resulting in a total of 28 patients dosed as of the date of this Current Report. Screening and enrollment are complete in the Phase 1/2 STAAR study and dosing of the remaining enrolled patients is expected in the first half of 2024. Productive discussions continue with the U.S. FDA and other health authorities on pathways to registration. The Company is deferring additional investments in planning for a potential registrational trial until a collaboration partnership or trial financing is secured. Summary of Updated Preliminary Clinical Data from Phase 1/2 STAAR Study of Isaralgagene Civaparvovec Announced on February 5, 2024 in Advance of Presentation at 20th Annual WORLD Symposium on February 7, 2024 The STAAR study is an ongoing Phase 1/2 multicenter, open-label, dose-ranging clinical study designed to assess the safety and tolerability of a single infusion of isaralgagene civaparvovec in Fabry disease patients 18 years of age. Patients are infused intravenously with a single dose and followed for 52 weeks. A separate long-term follow-up study is underway to monitor the patients treated in this study for up to five years following treatment. The study design provides for at least two patients to be dosed in each dose cohort, with a potential expansion in each cohort. Patients who are on stable enzyme repl

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation: the safety and efficacy and therapeutic and commercial potential of isaralgagene civaparvovec, the anticipated plans and timelines for conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, expectations regarding the conclusion of dosing in our Phase 1/2 STAAR study, the anticipated advancement of isaralgagene civaparvovec to late-stage development, including Sangamo's plans to seek a potential partner or additional financing to proceed with potential future Phase 3 trials of isaralgagene civaparvovec and the timing thereof, and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to our lack of capital resources to fully develop, obtain regulatory approval for and commercialize our product candidates, including our ability to secure the funding required to initiate a potential Phase 3 trial of isaralgagene civaparvovec in a timely manner or at all; our need for substantial additional funding to execute our operating plan and to continue to operate as a going concern; the effects of macroeconomic factors or financial challenges, including as a result of the ongoing overseas conflict, current or potential future bank failures, inflation and rising interest rates, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the operation of clinical trials; the research and development process, including the operation and results of clinical trials and the presentation of clinical data; the impacts of cl

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SANGAMO THERAPEUTICS, INC. Dated: February 6, 2024 By: /s/ SCOTT B. WILLOUGHBY Name: Scott B. Willoughby Title: Senior Vice President, General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR